ABSTRACT
Dorzolamide was the first carbonic anhydrase (CA) inhibitor available in an ophthalmic solution. It was introduced into the market in 1995 and was originally conceived as an alternative for oral carbonic anhydrase inhibitors (mainly acetazolamide) that are not well tolerated when administered chronically.
